| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Sarepta Therapeutics, Inc. (SRPT) has 14 insiders with recent SEC Form 4 filings, including 4 buys and 0 sells. SRPT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.98M | $52.66M | - | |
| CEO | 490.3K | $8.65M | - | |
| Pres | 227.2K | $4.01M | - | |
| Dir | 214.4K | $3.78M | - | |
| COO | 202.0K | $3.56M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2016 | Barry Richard70 | Director | Buy | 75,000 | $15.66 | $1,174,185.00 | +2.4% | |
| Mar 14, 2016 | Price Ben Gil | Director | Buy | 4,500 | $16.70 | $75,144.15 | +11.7% | |
| Feb 27, 2015 | Kaye Edward M. Md46 | SVP &Chief Medical Officer | Buy | 800 | $11.82 | $9,452.00 | +156.6% | |
| Feb 27, 2015 | Christopher Nishan Garabedian | President And CEO | Buy | 800 | $11.82 | $9,452.00 | +2.8% |